



# BAFNA PHARMACEUTICALS LTD.,

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHÉTTY STREET, CHENNAI-600 001, INDIA.  
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, email: info@bafnapharma.com, Website, www.bafnapharma.com  
CIN : L24294 TN1995PLC030698

Date: 03<sup>rd</sup> May 2021

Listing Department BSE Limited P J Towers, Dalal Street, Mumbai – 400 001 SCRIP CODE: 532989 SCRIP SYMBOL: BAFNAPHARM	Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Bandra (E), Mumbai – 400051 SCRIP SYMBOL: BAFNAPH
---	--

Dear Sir,

**Sub: Company update- United Kingdom (UK)- MHRA approval for packaging lines  
Ref: Regulation 30 of the SEBI (LODR) Regulations, 2015**

We would like to update you on the following:-

The Company has added two fully automated packaging lines to its existing capacity and they have been approved by the UK-MHRA (Medicines and Healthcare products Regulatory Agency) for the United Kingdom and the European Union (EU).

Commenting on the approval, Mr. Mahaveer Chand Bafna, CEO of Bafna Pharmaceuticals Ltd. says, "The approval from UK- MHRA will provide further momentum to our already expanding business in the UK, Europe and other Regulated Markets. This approval will enable Bafna Pharma to increase its output and consequentially generate higher revenue and profits.

Kindly request you to take the same on record.

Yours Sincerely,  
For BAFNA PHARMACEUTICALS LIMITED

Jitendra Kumar Pal  
Company Secretary

